CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 17, 2018--
Therapeutics, Inc. (NASDAQ:MCRB) today announced that new
preclinical data supporting the development of microbiome therapeutics
for immuno-oncology (leveraging gut microbiota to impact tumor
immunotherapy)1 will be presented today by Sceneay et al in
the late breaking poster session at the 2018 American Association for
Cancer Research Annual Meeting (AACR) in Chicago. The data
presented provide new insights on the potential mechanism by which
Seres’ microbiome therapies could improve the outcomes of cancer
patients treated with immune checkpoint inhibitors.
“The data presented at AACR provide important new models and mechanistic
insights that inform our planned development efforts to evaluate the
ability of microbiome therapy to augment immune checkpoint inhibitors,”
said David Cook, Ph.D., Chief Scientific Officer and Executive Vice
President of Research at Seres. “The insights described in this
presentation will guide the continued development of SER-401, which we
expect to enter clinical development later this year. Our objective is
to use our microbiome therapeutic approach to improve the efficacy of
immunotherapy in patients with life-threatening cancers.”
Seres presented results from preclinical studies designed to evaluate
the impact of various consortia of bacterial species on the anti-tumor
immune response in murine models following treatment with an anti-PD-1
checkpoint inhibitor. Results demonstrated that both germ-free mice
lacking a microbiome and antibiotics-treated mice with a dysbiotic
microbiome, failed to mount an effective anti-tumor response following
treatment with an anti-PD-1 checkpoint inhibitor. The response to
anti-PD-1 was restored in germ-free as well as antibiotics-treated mice
by introducing a diverse microbiome, and was driven by increased entry
of tumor-infiltrating lymphocytes into the tumor; specifically, CD8+ T
effector cells. Current pre-clinical efforts are focused on optimizing
specific microbiome compositions based on functional and phylogenetic
information to inform the development of therapeutic candidates.
Seres is developing SER-401, a preclinical stage oral microbiome therapy
comprising a consortium of live bacteria to improve the efficacy and
safety of immunotherapy. Through a collaboration with The University of
Texas MD Anderson Cancer Center and the Parker Institute for Cancer
Immunotherapy, Seres plans to initiate a clinical study in patients with
advanced metastatic melanoma later this year. In a 2017 study published
in Science, the MD Anderson research team, led by Dr. Jennifer
Wargo, described a microbiome signature associated with response to
checkpoint inhibitor therapy. A planned clinical trial will evaluate the
impact of an anti-PD-1 checkpoint inhibitor with adjunctive microbiome
therapy on patient outcomes.
About Seres Therapeutics
Seres Therapeutics, Inc., is a leading microbiome therapeutics platform
company developing a novel class of biological drugs that are designed
to treat disease by restoring the function of a dysbiotic microbiome,
where the natural state of bacterial diversity and function is
imbalanced. Seres’ lead program, SER-109, has obtained Breakthrough
Therapy and Orphan Drug designations from the U.S. Food and Drug
Administration and is in Phase 3 development for multiply recurrent C. difficile infection.
Seres’ clinical candidate SER-287 has successfully completed a Phase 1b
study in patients with mild-to-moderate Ulcerative Colitis. Seres is
also developing SER-262, the first ever synthetic microbiome therapeutic
candidate, in a Phase 1b study in patients with primary C.
difficile infection. For more information, please visit www.serestherapeutics.com.
Follow us on Twitter @SeresTx.
1. Sceneay, Jaclyn et. al., Leveraging gut microbiota to impact tumor
immunotherapy. Poster. American Association for Cancer Research Annual
View source version on businesswire.com: https://www.businesswire.com/news/home/20180417005622/en/
Source: Seres Therapeutics, Inc.
Carlo Tanzi, Ph.D., 617-203-3467
President, Investor Relations and Corporate Communications